Viatris Inc.’s $7.45 Billion Debt Exchange Offer
October 28, 2021
Cravath represented Viatris Inc. in connection with its debt exchange offer totaling up to $7.45 billion. Viatris Inc. is a global healthcare company delivering increased access to affordable, quality medicines for patients worldwide. The transaction expired on October 28, 2021.
The Cravath team included partner Matthew G. Jones and associate Caroline B. Bowman on capital markets matters, and senior attorney Kiran Sheffrin and associates Alissa B. Fromkin and Sonia Katharani‑Khan on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2013, Columbia Law SchoolHarlan Fiske Stone Scholar; James Kent Scholar
-
B.A., 2010, Cornell University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
December 06, 2025
Viatris’s Sale of its Equity Stake in Biocon Biologics Limited to Biocon
On December 6, 2025, Viatris Inc. (“Viatris”), a global healthcare company, announced it has entered into definitive agreements with Biocon Limited (“Biocon”) for the sale of Viatris’s equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon will acquire all of Viatris’s convertible preferred equity in Biocon Biologics Limited for a total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
February 28, 2024
Viatris’s Global Research and Development Collaboration with Idorsia
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
